1. Li, R., Ng, T. S. C., Wang, S. J., Prytyskach, M., Rodell, C. B., Mikula, H., Kohler, R. H., Garlin, M. A., Lauffenburger, D. A., Parangi, S., Dinulescu, D. M., Bardeesy, N., Weissleder, R., & Miller, M. A. (2021). Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nature Nanotechnology, 16(7), 830–839.
  2. Dejene, S. B., Ohman, A. W., Du, W., Randhawa, D., Bradley, A., Yadav, N., Elias, K. M., Dinulescu, D. M., & Setlur, S. R. (2019). Defining fallopian tube-derived miRNA cancer signatures. Cancer Medicine, 8(15), 6709–6716.
  3. Hüttenhain, R., Choi, M., Martin de la Fuente, L., Oehl, K., Chang, C.-Y., Zimmermann, A.-K., Malander, S., Olsson, H., Surinova, S., Clough, T., Heinzelmann-Schwarz, V., Wild, P. J., Dinulescu, D. M., Niméus, E., Vitek, O., & Aebersold, R. (2019). A targeted mass spectrometry strategy for developing proteomic biomarkers: A case study of epithelial ovarian cancer. Molecular & Cellular Proteomics: MCP, 18(9), 1836–1850.
  4. Baldwin, P., Ohman, A. W., Medina, J. E., McCarthy, E. T., Dinulescu, D. M., & Sridhar, S. (2019). Nanoformulation of Talazoparib delays tumor progression and ascites formation in a late stage cancer model. Frontiers in Oncology, 9, 353.
  5. Wang, H., Feng, Z., Yang, C., Liu, J., Medina, J. E., Aghvami, S. A., Dinulescu, D. M., Liu, J., Fraden, S., & Xu, B. (2019). Unraveling the cellular mechanism of assembling cholesterols for selective cancer cell death. Molecular Cancer Research: MCR, 17(4), 907–917.
  6. Soong, T. R., Dinulescu, D. M., Xian, W., & Crum, C. P. (2018). Frontiers in the pathology and pathogenesis of ovarian cancer: Cancer precursors and “precursor escape.” Hematology/Oncology Clinics of North America, 32(6), 915–928.
  7. Tucker, D. W., Getchell, C. R., McCarthy, E. T., Ohman, A. W., Sasamoto, N., Xu, S., Ko, J. Y., Gupta, M., Shafrir, A., Medina, J. E., Lee, J. J., MacDonald, L. A., Malik, A., Hasselblatt, K. T., Li, W., Zhang, H., Kaplan, S. J., Murphy, G. F., Hirsch, M. S., … Dinulescu, D. M. (2018). Epigenetic reprogramming strategies to reverse global loss of 5-hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 24(6), 1389–1401.
  8. Kolin, D. L., Dinulescu, D. M., & Crum, C. P. (2018). Origin of clear cell carcinoma: nature or nurture? The Journal of Pathology, 244(2), 131–134.
  9. Baldwin, P., Ohman, A. W., Tangutoori, S., Dinulescu, D. M., & Sridhar, S. (2018). Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. International Journal of Nanomedicine, 13, 8063–8074.
  10. Li, J., Shi, J., Medina, J. E., Zhou, J., Du, X., Wang, H., Yang, C., Liu, J., Yang, Z., Dinulescu, D. M., & Xu, B. (2017). Selectively inducing cancer cell death by intracellular enzyme-instructed self-assembly (EISA) of dipeptide derivatives. Advanced Healthcare Materials, 6(15).
  11. Hua, Y., Choi, P.-W., Trachtenberg, A. J., Ng, A. C., Kuo, W. P., Ng, S.-K., Dinulescu, D. M., Matzuk, M. M., Berkowitz, R. S., & Ng, S.-W. (2016). Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma. Oncotarget, 7(40), 66077–66086.
  12. Kulkarni, A., Pandey, P., Rao, P., Mahmoud, A., Goldman, A., Sabbisetti, V., Parcha, S., Natarajan, S. K., Chandrasekar, V., Dinulescu, D., Roy, S., & Sengupta, S. (2016). Algorithm for designing nanoscale supramolecular therapeutics with increased anticancer efficacy. ACS Nano, 10(9), 8154–8168.
  13. Li, J., Kuang, Y., Shi, J., Zhou, J., Medina, J. E., Zhou, R., Yuan, D., Yang, C., Wang, H., Yang, Z., Liu, J., Dinulescu, D. M., & Xu, B. (2015). Enzyme-instructed intracellular molecular self-assembly to boost activity of cisplatin against drug-resistant ovarian cancer cells. Angewandte Chemie (International Ed. in English), 54(45), 13307–13311.
  14. Hasan, N., Ohman, A. W., & Dinulescu, D. M. (2015). The promise and challenge of ovarian cancer models. Translational Cancer Research, 4(1), 14–28.
  15. Ohman, A. W., Hasan, N., & Dinulescu, D. M. (2014). Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. Frontiers in Oncology, 4, 322.
  16. Morgan, S. L., Medina, J. E., Taylor, M. M., & Dinulescu, D. M. (2014). Targeting platinum resistant disease in ovarian cancer. Current Medicinal Chemistry, 21(26), 3009–3020.
  17. Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., Karst, A. M., Hirsch, M. S., Setlur, S. R., Crum, C. P., Dinulescu, D. M., & Drapkin, R. (2013). Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell, 24(6), 751–765.
  18. Kulkarni, A. A., Roy, B., Rao, P. S., Wyant, G. A., Mahmoud, A., Ramachandran, M., Sengupta, P., Goldman, A., Kotamraju, V. R., Basu, S., Mashelkar, R. A., Ruoslahti, E., Dinulescu, D. M., & Sengupta, S. (2013). Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Research, 73(23), 6987–6997.
  19. Morgan, Stefanie L., Wyant, G. A., & Dinulescu, D. M. (2013). “Take it up a NOTCH”: novel strategies for cancer therapy: ” Novel strategies for cancer therapy. Cell Cycle (Georgetown, Tex.), 12(2), 191–192.
  20. McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, J. C., Poole, B. B., Cheng, K.-H., Daggett, J., Jr, Cullen, K., Kantoff, E., Hasselbatt, K., Berkowitz, J., Muto, M. G., Berkowitz, R. S., Aster, J. C., Matulonis, U. A., & Dinulescu, D. M. (2012). Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences of the United States of America, 109(43), E2939-48.
  21. Sengupta, P., Basu, S., Soni, S., Pandey, A., Roy, B., Oh, M. S., Chin, K. T., Paraskar, A. S., Sarangi, S., Connor, Y., Sabbisetti, V. S., Kopparam, J., Kulkarni, A., Muto, K., Amarasiriwardena, C., Jayawardene, I., Lupoli, N., Dinulescu, D. M., Bonventre, J. V., … Sengupta, S. (2012). Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 109(28), 11294–11299.
  22. Taguchi, A., Politi, K., Pitteri, S. J., Lockwood, W. W., Faça, V. M., Kelly-Spratt, K., Wong, C.-H., Zhang, Q., Chin, A., Park, K.-S., Goodman, G., Gazdar, A. F., Sage, J., Dinulescu, D. M., Kucherlapati, R., Depinho, R. A., Kemp, C. J., Varmus, H. E., & Hanash, S. M. (2011). Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell, 20(3), 289–299.
  23. Dinulescu, D. (2012). Molecular mechanisms underlying endometriosis and endometriosis-related cancers. In Endometriosis (pp. 512–518). Wiley-Blackwell.
  24. Paraskar, A. S., Soni, S., Chin, K. T., Chaudhuri, P., Muto, K. W., Berkowitz, J., Handlogten, M. W., Alves, N. J., Bilgicer, B., Dinulescu, D. M., Mashelkar, R. A., & Sengupta, S. (2010). Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America, 107(28), 12435–12440.
  25. Pitteri, S. J., JeBailey, L., Faça, V. M., Thorpe, J. D., Silva, M. A., Ireton, R. C., Horton, M. B., Wang, H., Pruitt, L. C., Zhang, Q., Cheng, K. H., Urban, N., Hanash, S. M., & Dinulescu, D. M. (2009). Correction: Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PloS One, 4(12).
  26. Romero, I. L., Gordon, I. O., Jagadeeswaran, S., Mui, K. L., Lee, W. S., Dinulescu, D. M., Krausz, T. N., Kim, H. H., Gilliam, M. L., & Lengyel, E. (2009). Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prevention Research (Philadelphia, Pa.), 2(9), 792–799.
  27. Zhang, Q., Menon, R., Deutsch, E. W., Pitteri, S. J., Faca, V. M., Wang, H., Newcomb, L. F., Depinho, R. A., Bardeesy, N., Dinulescu, D., Hung, K. E., Kucherlapati, R., Jacks, T., Politi, K., Aebersold, R., Omenn, G. S., States, D. J., & Hanash, S. M. (2008). A mouse plasma peptide atlas as a resource for disease proteomics. Genome Biology, 9(6), R93.
  28. Abbott, K. L., Nairn, A. V., Hall, E. M., Horton, M. B., McDonald, J. F., Moremen, K. W., Dinulescu, D. M., & Pierce, M. (2008). Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics, 8(16), 3210–3220.
  29. Park, S.-M., Shell, S., Radjabi, A. R., Schickel, R., Feig, C., Boyerinas, B., Dinulescu, D. M., Lengyel, E., & Peter, M. E. (2007). Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (Georgetown, Tex.), 6(21), 2585–2590.
  30. Kirsch, D. G., Dinulescu, D. M., Miller, J. B., Grimm, J., Santiago, P. M., Young, N. P., Nielsen, G. P., Quade, B. J., Chaber, C. J., Schultz, C. P., Takeuchi, O., Bronson, R. T., Crowley, D., Korsmeyer, S. J., Yoon, S. S., Hornicek, F. J., Weissleder, R., & Jacks, T. (2007). A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine, 13(8), 992–997.
  31. Pieretti-Vanmarcke, R., Donahoe, P. K., Pearsall, L. A., Dinulescu, D. M., Connolly, D. C., Halpern, E. F., Seiden, M. V., & MacLaughlin, D. T. (2006). Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 103(46), 17426–17431.
  32. Szotek, P. P., Pieretti-Vanmarcke, R., Masiakos, P. T., Dinulescu, D. M., Connolly, D., Foster, R., Dombkowski, D., Preffer, F., Maclaughlin, D. T., & Donahoe, P. K. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proceedings of the National Academy of Sciences of the United States of America, 103(30), 11154–11159.
  33. Daikoku, T., Tranguch, S., Trofimova, I. N., Dinulescu, D. M., Jacks, T., Nikitin, A. Y., Connolly, D. C., & Dey, S. K. (2006). Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Research, 66(5), 2527–2531.
  34. Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D., & Jacks, T. (2005). Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature Medicine, 11(1), 63–70.
  35. Dinulescu, D. M., Wood, L. J., Shen, L., Loriaux, M., Corless, C. L., Gross, A. W., Ren, R., Deininger, M. W. N., & Druker, B. J. (2003). c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene, 22(55), 8852–8860.
  36. Robinson, S. W., Dinulescu, D. M., & Cone, R. D. (2000). Genetic models of obesity and energy balance in the mouse. Annual Review of Genetics, 34(1), 687–745.
  37. Fan, W., Dinulescu, D. M., Butler, A. A., Zhou, J., Marks, D. L., & Cone, R. D. (2000). The central melanocortin system can directly regulate serum insulin levels. Endocrinology, 141(9), 3072–3079.
  38. Dinulescu, D. M., & Cone, R. D. (2000). Agouti and agouti-related protein: analogies and contrasts. The Journal of Biological Chemistry, 275(10), 6695–6698.
  39. Cowley, M. A., Pronchuk, N., Fan, W., Dinulescu, D. M., Colmers, W. F., & Cone, R. D. (1999). Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron, 24(1), 155–163.
  40. Dinulescu, D. M., Fan, W., Boston, B. A., McCall, K., Lamoreux, M. L., Moore, K. J., Montagno, J., & Cone, R. D. (1998). Mahogany (mg) stimulates feeding and increases basal metabolic rate independent of its suppression of agouti. Proceedings of the National Academy of Sciences of the United States of America, 95(21), 12707–12712.